GLP-1 agonist liraglutide improves ouabain-induced mania and depressive state via GSK-3β pathway

References

• Leboyer M, Kupfer DJ. Bipolar disorder: new perspectives in health care and prevention. J Clin Psychiatry. 2010;71(12):1689–1695.
   PubMed Web of Science ®Google Scholar
• Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241.
   PubMed Web of Science ®Google Scholar
• Torpy JM. Bipolar disorder. JAMA. 2009;301(5):564.
   PubMed Web of Science ®Google Scholar
• Connolly KR, Thase ME. The clinical management of bipolar disorder. Prim Care Companion CNS Disord. 2011;13:PCC.10r01097.
   PubMedGoogle Scholar
• Lichtstein D, Ilani A, Rosen H, et al. Na+, K+-ATPase signaling and bipolar disorder. Int J Mol Sci. 2018;19(8):2314.
   Web of Science ®Google Scholar
• El-Mallakh RS, Gao Y, You P. Role of endogenous ouabain in the etiology of bipolar disorder. Int J Bipolar Disord. 2021;9(1):6.
   PubMed Web of Science ®Google Scholar
• Valvassori SS, Dal-Pont GC, Resende WR, et al. Validation of the animal model of bipolar disorder induced by ouabain: face, construct and predictive perspectives. Transl Psychiatry. 2019;9(1):158.
   PubMedGoogle Scholar
• Valvassori SS, Dal-Pont GC, Varela RB, et al. Ouabain induces memory impairment and alter the BDNF signaling pathway in an animal model of bipolar disorder: cognitive and neurochemical alterations in BD model. J Affect Disord. 2021;282:1195–1202.
   PubMed Web of Science ®Google Scholar
• Riegel RE, Valvassori SS, Elias G, et al. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem Int. 2009;55(7):491–495.
   PubMed Web of Science ®Google Scholar
• Luca A, Calandra C, Luca M. Gsk3 signalling and redox status in bipolar disorder: evidence from lithium efficacy. Oxid Med Cell Longev. 2016;2016:3030512–3030547.
   Web of Science ®Google Scholar
• Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther. 2015;148:114–131.
   PubMed Web of Science ®Google Scholar
• Łojko D, Owecki M, Suwalska A. Impaired glucose metabolism in bipolar patients: the role of psychiatrists in its detection and management. Int J Environ Res Public Health. 2019;16(7):1132.
   Web of Science ®Google Scholar
• Calkin CV. Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Ann Med. 2019;51(5–6):281–293.
   PubMed Web of Science ®Google Scholar
• Fineman MS, Cirincione BB, Maggs D, et al. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes Obes Metab. 2012;14(8):675–688.
   PubMed Web of Science ®Google Scholar
• Salcedo I, Tweedie D, Li Y, et al. Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders. Br J Pharmacol. 2012;166(5):1586–1599.
   PubMed Web of Science ®Google Scholar
• Bertelli PR, Mocelin R, Marcon M, et al. Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110388.
   PubMedGoogle Scholar
• Wiciński M, Socha M, Malinowski B, et al. Liraglutide and its neuroprotective properties—focus on possible biochemical mechanisms in Alzheimer's disease and cerebral ischemic events. Int J Mol Sci. 2019;20(5):1050.
   Web of Science ®Google Scholar
• Chaves Filho AJM, Cunha NL, de Souza AG, et al. The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2020;99:109872.
   PubMed Web of Science ®Google Scholar
• Percie Du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410.
   PubMed Web of Science ®Google Scholar
• Jornada LK, Valvassori SS, Steckert AV, et al. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J Psychiatr Res. 2011;45(2):162–168.
   PubMed Web of Science ®Google Scholar
• Zeng SS, Bai JJ, Jiang H, et al. Treatment with liraglutide exerts neuroprotection after hypoxic–ischemic brain injury in neonatal rats via the PI3K/AKT/GSK3β pathway. Front Cell Neurosci. 2019;13:585.
   PubMed Web of Science ®Google Scholar
• Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666–679.
   PubMed Web of Science ®Google Scholar
• Kanazawa LKS, Vecchia DD, Wendler EM, et al. Effects of acute and chronic quercetin administration on methylphenidate-induced hyperlocomotion and oxidative stress. Life Sci. 2017;171:1–8.
   PubMed Web of Science ®Google Scholar
• Serchov T, van Calker D, Biber K. Sucrose preference test to measure anhedonic behaviour in mice. Bio-Protocol. 2016;6(19): e1958.
   Google Scholar
• Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc. 2012;7(6):1009–1014.
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193(1):265–275.
   PubMed Web of Science ®Google Scholar
• He F. BCA (bicinchoninic acid) protein assay. Bio-Protocol. 2011;101(5):e44.
   Google Scholar
• Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103–1111.
   PubMed Web of Science ®Google Scholar
• Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277–285.
   PubMed Web of Science ®Google Scholar
• Valvassori SS, Dal-Pont GC, Resende WR, et al. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain. Neuropharmacology. 2017;117:447–459.
   PubMed Web of Science ®Google Scholar
• Bertelli PR, Mocelin R, Marcon M, et al. Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110388.
   Google Scholar
• Weina H, Yuhu N, Christian H, et al. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res. 2018;1694:55–62.
   PubMed Web of Science ®Google Scholar
• Salim S. Oxidative stress and psychological disorders. Curr Neuropharmacol. 2014;12(2):140–147.
   PubMed Web of Science ®Google Scholar
• de Sousa RT, Zarate CA, Zanetti MV, et al. Oxidative stress in early stage bipolar disorder and the association with response to lithium. J Psychiatric Res. 2014;50:36–41.
   PubMed Web of Science ®Google Scholar
• Wang J-F, Shao L, Sun X, et al. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 2009;11(5):523–529.
   PubMed Web of Science ®Google Scholar
• Joshi YB, Praticò D. Lipid peroxidation in psychiatric illness: overview of clinical evidence. Oxid Med Cell Longev. 2014;2014:828702–828705.
   PubMed Web of Science ®Google Scholar
• Steckert AV, Valvassori SS, Moretti M, et al. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res. 2010;35(9):1295–1301.
   PubMed Web of Science ®Google Scholar
• Brocardo PS, Budni J, Pavesi E, et al. Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disord. 2010;12(4):414–424.
   PubMed Web of Science ®Google Scholar
• Valvassori SS, Dal-Pont GC, Steckert AV, et al. Sodium butyrate has an antimanic effect and protects the brain against oxidative stress in an animal model of mania induced by ouabain. Psychiatry Res. 2016;235:154–159.
   PubMed Web of Science ®Google Scholar
• Sivalingam S, Larsen EL, van Raalte DH, et al. The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes. Sci Rep. 2021;11(1):10624.
   Web of Science ®Google Scholar
• Milani L, Galindo CM, Turin de Oliveira NM, et al. The GLP-1 analog liraglutide attenuates acute liver injury in mice. Ann Hepatol. 2019;18(6):918–928.
   PubMed Web of Science ®Google Scholar
• Abbas NAT, Kabil SL. Liraglutide ameliorates cardiotoxicity induced by doxorubicin in rats through the Akt/GSK-3β signaling pathway. Naunyn Schmiedebergs Arch Pharmacol. 2017;390(11):1145–1153.
   PubMed Web of Science ®Google Scholar
• Yang K, Chen Z, Gao J, et al. The key roles of GSK-3β in regulating mitochondrial activity. Cell Physiol Biochem. 2017;44(4):1445–1459.
   PubMedGoogle Scholar
• Wildburger NC, Laezza F. Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase. Front Mol Neurosci. 2012;5:80.
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Moechars D, Cryns K, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J Neurosci. 2006;26(35):9022–9029.
   PubMed Web of Science ®Google Scholar
• Lopachev A, Volnova A, Evdokimenko A, et al. Intracerebroventricular injection of ouabain causes mania-like behavior in mice through D2 receptor activation. Sci Rep. 2019;9(1):15627.
   PubMedGoogle Scholar
• Kukula O, Çiçekli MN, Şafak S, et al. Role of TRPV1 channels on glycogen synthase kinase-3β and oxidative stress in ouabain-induced bipolar disease. J Recept Signal Transduction. 2021;26:1–11.
   Google Scholar
• Zhu H, Zhang Y, Shi Z, et al. The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci Rep. 2016;6(1):26859.
   PubMedGoogle Scholar